April 3, 2015 : Episode 1

Video

Abiraterone Label Expanded, Phase III Melanoma Data, SGR Repeal, and More

Related Videos
Marc-Oliver Grimm, MD
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Stephen J. Freedland, MD, and Eleni Efstathiou, MD, PhD, experts on prostate cancer
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Marc-Oliver Grimm, MD
2 KOLs are featured in this panel.
2 KOLs are featured in this panel.
Atish D. Choudhury, MD, PhD
2 KOLs are featured in this panel.
Related Content
Christian Behrenbruch PhD, MBA
July 24th 2024

FDA Accepts the New Drug Application for TLX007-CDx Kit in Prostate Cancer

Jeffrey S. Weber, MD, PhD
November 6th 2023

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

Suthee Rapisuwon, MD
July 16th 2024

Adjuvant Nivolumab/Ipilimumab Lengthens DMFS in High-Risk Uveal Melanoma

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Neil D. Gross, MD, FACS
July 10th 2024

Neoadjuvant Cemiplimab Underscores Push to Bolster Treatment of CSCC

Madan Jagasia, MD, chief executive officer of Obsidian Therapeutics
July 9th 2024

OBX-115 Earns FDA Fast Track Designation for Advanced Melanoma